Hikma launches caffeine citrate injection

RNS Number : 8442M

Hikma Pharmaceuticals Plc

12 May 2015

 



PRESS RELEASE

Hikma launches caffeine citrate injection, commercialising the first of the Bedford products

London, 12 May 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has launched CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL).  CAFCIT® is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.

Said Darwazah, Chairman and CEO of Hikma said, "This is our first launch from the Bedford portfolio acquired last year.  We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."

According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.

--  ENDS  --

Enquiries

Hikma Pharmaceuticals PLC                                                       

Susan Ringdal, VP Corporate Strategy and Investor Relations                      [phone]/ [phone]

Lucinda Henderson, Deputy Head of Investor Relations                                 [phone]/ [phone]

Zeena Murad, Investor Relations Manager                                                            [phone]/ [phone]

FTI Consulting                                                                                  

Ben Atwell/ Matthew Cole                                                                                           [phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million. 

 

END

 

 

NRAUAOWRVOAVAAR